Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Had 1 or more paid pharmacy claims for ribociclib with the first claim for the CDK4/6i observed between 26 February 2018 and 31 December 2022 (i.e., during the index period)
* With the index CDK4/6i used in combination with an endocrine-based therapy, that is an aromatase inhibitor (i.e., letrozole, anastrozole, or exemestane), or fulvestrant, as 1L treatment for mBC
* With the endocrine therapy (ET) initiated within 60 days of the first paid pharmacy claim of the index CDK4/6i; ET may have been initiated no earlier than 60 days prior to the index date (expected window for insurance approval of the CDK4/6i as 1L treatment for mBC in a real-world setting)
Adult who was 18 years of age or older as of the index date
Had 2 or more medical service claims with a code for breast cancer (BC) separated by 30 days or more, and 1 or more claims with a code for BC prior to the index date
Had 2 or more medical service claims with a code for a secondary neoplasm separated by 30 days or more, with the first code for a secondary neoplasm occurring not earlier than 30 days from the first diagnosis for BC, and 1 or more claims with a code for a secondary neoplasm prior to the index date
Had continuous health plan enrollment for 12 months or more prior to and 1 month or more after the index date
Had a diagnosis for other primary cancers (other than BC) before the first diagnosis for secondary neoplasm
Had prior treatments for BC (i.e., chemotherapy, targeted therapy, ET \[except ≤60 days prior to index date\], or immunotherapy) during the 12-month washout period (relapsed/progressed ≤12 months prior to index date)
Had prior surgical procedure for BC during the 12-month washout period (relapsed/progressed ≤12 months prior to index date)
Had evidence of participation in a clinical trial prior to or at the index date (International Classification of Disease, 10th Edition, Clinical Modification \[ICD-10-CM\]: Z00.6)
